DSK Legal | View firm profile
DSK Legal advised and assisted OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited) (the “Company”) in connection with the filing of the Information Memorandum pursuant to the scheme of arrangement amongst Strides Pharma Science Limited,
Steriscience Specialties Private Limited and the Company (the “Scheme”) for the listing of 11,44,36,021 equity shares of ₹1 each of the Company. The Company is a fully integrated, multi-modality specialty pharmaceutical contract development and manufacturing organisation company, focused on developing and manufacturing drug device combinations, biologics, sterile injectables and oral technologies like soft gelatin capsules. The Scheme got sanctioned by the NCLT, Mumbai on November 14, 2024, and the Information Memorandum was filed with BSE and NSE on January 21, 2025. The Equity Shares of the Company got listed on BSE and NSE on January 24, 2025.
DSK Legal assisted the Company inter alia in the (i) conducting diligence and drafting of the Information Memorandum; (ii) drafting of all board resolutions and shareholder resolutions; (iii) drafting and commenting on the standard certificates, auditor certificates and advertisements; and (iv) reviewing and commenting on SEBI applications.
The deal team consisted of the following:
Mr. Avinash Poojari (Associate Partner), Ms. Akanksha Dubey (Principal Associate) and Ms. Sachi Ray (Associate).
Mr. Anand Desai (Managing Partner) acted as the engagement and relationship partner.